Difei Yang Recent News
Brean Assumes SCYNEXIS Shares At Buy, Sees 300% Upside
Alder BioPharma Could Lead The Migraine Market; Brean Assumes With Buy Rating
Brean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy
Akebia Price Target Lowered, Still A Buy At Brean
Brean Downgrades Pernix Therapeutics, Warns Of Unclear Path To Profitability
Galencia's Bid For Relypsa Is 'Reasonable,' Another Bidder 'Unlikely'
Evoke Pharma Plunges 70%, Prompting Brean To Downgrade The Stock From Buy
June Data On Relypsa's Veltassa 'Very Encouraging'
Brean Downgrades Revance Therapeutics Following RT-001 Fail
Brean Reiterates Buy Rating On Revance Ahead Of Upcoming Phase 3 Read-Out
Brean Thinks Relypsa's Veltassa Sales Were 'Solid, But Not Impressive'
Brean's Yang: Relypsa Monthly Prescription Data Met Expectations, A Takeout Still 'Probable'
Brean Initiates Relypsa With Buy Rating, $26 Target
Brean: Pernix Deal Could Occur Soon, Stock Worth $8
Brean Reiterates Buy On Horizon Pharma, Likes Crealta Deal
Premium No Longer Deserved? Why Brean's Difei Yang Is Downgrading Horizon Pharma
Brean Capital Initiates Coverage On Osiris Therapeutics
Brean Capital Initiates Coverage On Zogenix
Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix
Could ViroPharma Benefit from Multiple Generic Versions of VANCOCIN?